
|Videos|July 1, 2021
Efficacy of Dapagliflozin in the Treatment of Patients With Type 2 diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained what some of the findings were around the efficacy of dapagliflozin in patients during the DARE-19 trial.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Calcium Gap: How Pharmacists Can Guide Patients Toward Better Bone Health
2
COVID-19 Vaccination in Medically Complex Adults
3
Testing categories in practice — clinical conversations
4
The Vaccine Schedule Just Changed Again—Here’s What's Real and What Isn't
5






































































































